[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Augusta University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":453},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,42,71,99,124,155,185,209,231,255,277,301,323,347,376,401,431],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100520561","effects-of-home-base-whole-body-vibration-in-osteoarthritis-vibe-rx2-100520561",false,"NCT06058169","Effects of Home Base Whole-body Vibration in Osteoarthritis. (VIBE-Rx2)","Pilot Investigation on the Effects of Sub Acute (12 Week) Home Base Whole-body Vibration Training in Osteoarthritis.","Inclusion Criteria:\n\n* Symptomatic Osteoarthritic knee pain for at least 6 months.\n* Mean and women\n* Ages 40-75 years old\n\nExclusion Criteria:\n\n* \\\u003C40 years old or \\>75 years old\n* History of balance issues\n* History of falls\n* Epilepsy\n* Pregnancy\n* The use of whole-body vibration in the past 6 months\n* Previous knee surgery within last 3 years\n* Unable to stand for at least 20 minutes (for whole body vibration training)","ALL","40 Years","75 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this proposal is to understand how the Vibrant Health Ultimate whole-body vibration (WBV) machine affects pain and inflammation in older adults. The investigators' hypothesize that sub-acute (12 weeks) WBV will lead to improvement in the level of knee pain and improve vascular function via a decrease in systemic inflammation.",[27,28],"Whole Body Vibration","Osteo Arthritis Knee","RECRUITING","2026-05-12",{"date":32,"type":33},"2026-05-14","ACTUAL",{"date":35,"type":33},"2025-04-25",{"date":37,"type":21},"2026-09-01",{"name":39,"class":40},"Augusta University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":41},"100527025","early-phase-1-pilot-study-dara-cybord-in-newly-diagnosed-multiple-myeloma-patients-with-renal-failure-100527025","NCT06142396","Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure","Pilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD) in Newly Diagnosed Multiple Myeloma Patients With Renal Failure","Inclusion Criteria:\n\n1. Patients must have had a confirmed new diagnosis of MM following revised IMWG criteria.\n2. Patients must have Zubrod\u002FECOG Performance Status ≤ 2.\n3. Patients must have renal insufficiency. Renal insufficiency is defined as eCrCl \\\u003C 60 mL\u002Fmin (using Cockcroft-Gault Equation for Cr Cl) and\u002For necessitating dialysis\n4. must not have known allergies to any of the study drugs. Must have adequate organ function.\n5. International normalized ratio (INR) and prothrombin time (PT) ≤1.5 × ULN. Activated partial thromboplastin time (aPTT) ≤1.5 × ULN.\n\nExclusion Criteria:\n\n* 1\\. Known seropositive for: human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C.\n\n  2\\. Known Chronic obstructive pulmonary disease (COPD). 3. Known Moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification.\n\n  4\\. Known Clinically significant heart disease is defined as: myocardial infarction within 6 months before enrollment, or unstable or uncontrolled disease\u002Fcondition related to or affection cardiac function.\n\n  5\\. Women who are pregnant, breastfeeding, or planning to become pregnant while enrolled in this study.\n\n  6\\. Patients with grade 3 or 4 peripheral neuropathy 7. Patients with other active malignancies that require concurrent treatment 8. Known CNS involvement or plasma cell leukemia, or AL amyloidosis 9. Participants with active infection requiring systemic therapy 10. Has known substance abuse disorders that would interfere with cooperation with the requirements of the study.","18 Years","80 Years",{"count":20,"type":21},[53],"EARLY_PHASE1","The goal of this study is to assess the efficacy of induction treatment with daratumumab-hyaluronidase (dara SC) with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for four cycles in patients with newly diagnosed multiple myeloma who have new onset renal failure. This study will also investigate the difference responses in African American (AA) patients versus non-African American patients.\n\nThe primary questions this study aims to answer are:\n\n1. To evaluate the very good partial response rate (VGPR) after 4 cycles of Dara-CyBord.\n2. To evaluate the renal response rate (RRR) after 4 cycles of Dara-CyBord.",[56,57],"Multiple Myeloma","Renal Failure",[59,60,61,62],"Daratumumab","Bortezomib","Cyclophosphamide","Dexamethasone","2026-03-11",{"date":65,"type":33},"2026-03-12",{"date":67,"type":33},"2024-11-01",{"date":69,"type":21},"2027-11-01",{"name":39,"class":40},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":41},"100609707","phase-1-a-trial-to-test-intermittent-deep-brain-stimulation-of-nucleus-basalis-of-meynert-to-treat-alzheimers-100609707","NCT07218081","A Trial to Test Intermittent Deep Brain Stimulation of Nucleus Basalis of Meynert to Treat Alzheimers.","Cognitive Brain Aging Reversal From Deep Brain Stimulation for Alzheimer's Dementia: a Clinical Trial.","Inclusion Criteria:\n\n* Age:65 minimum\n\n  * Age:85 maximum\n  * Probable, early-stage Alzheimer's Disease, as defined by NIA-AA 2018 criteria and positive PET for beta amyloid,\n  * no Lewy-Body-dementia or other form of dementia\n  * Clinical Dementia Rating (CDR) global score of 0.5-1.0 with a CBR-sb score from 2 to 6.\n  * MMSE ≥ 21\n  * stable psychopharmacological medication equivalent to 10 mg\u002Fday donepezil or less for at least 60 days\n  * valid informed consent\n  * an available caregiver willing to participate\n  * subject is living at home and likely to remain at home for the study duration\n  * Geriatric Depression Scale of 5 or less\n  * Columbia Suicide Severity Rating Scale \"No\" on questions 3 through 5\n  * Neuropsychiatric Inventory (NPI-Q) under 2 on 'Delusions', 'Hallucinations' or 'Agitation\u002FAggression' subscales\n\nExclusion Criteria:\n\n* • clinical co-morbidity interfering with study (e.g. head trauma requiring medical treatment in the 2 years prior, brain tumor, subdural hematoma, or other clinically significant space-occupying lesion on brain CT or MRI), or other implant precluding high field MRI scans.\n\n  * current major psychiatric disorder such as schizophrenia, bipolar disorder or major depressive disorder based on psychiatric consult at screening visit, or past medical history prior suicidal attempts or suicidal crises\n  * Another concurrent CNS condition (ie, stroke, Parkinson's disease, Lewy-Body dementia or other form of dementia, other evidence of significant structural brain pathology).\n  * Medical history of seizure disorder including epilepsy\n  * Terminal illness associated with expected survival of \\\u003C30 months\n  * Subjects with one of these other forms of dementia in the DSM-5 heading of Neurocognitive Disorders: Lewy body disease, Frontotemporal lobar degeneration, Vascular disease, Traumatic brain injury, HIV infection, Prion disease, Parkinson's disease, Huntington's disease, or due to multiple etiologies\n  * Subjects with unstable medical and neurological conditions at the discretion of the Principle Investigator","65 Years","85 Years",{"count":81,"type":21},12,[83],"PHASE1","The purpose of this study is to test a new procedure to treat Alzheimer's disease. The procedure is called intermittent Deep Brain Stimulation (DBS) of the nucleus basalis of Meynert. There will be up to six participants enrolled at Wellstar MCG Memory Clinic. There will be another six participants similarly enrolled to act as a control group that does not receive DBS. This second group will document the course of progression of Alzheimer's disease under the normal standard of care. The main goal of the study is to determine if DBS can sustain or improve cognition in Alzheimer's disease for at least two years. Participant data, with identifying information removed, may be shared with online repositories for comparison with trials with similar subjects.",[86],"Alzheimer Dementia (AD)",[88,89,90],"deep brain stimulation","alzheimer's","nucleus basalis of Meynert","2026-01-05",{"date":93,"type":33},"2026-01-07",{"date":95,"type":21},"2026-02-01",{"date":97,"type":21},"2028-11",{"name":39,"class":40},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":41},"100555586","transition-from-donor-milk-a-feasibility-study-100555586","NCT06514014","Transition From Donor Milk: a Feasibility Study","Inclusion Criteria:\n\n1. Greater than 1,250 grams\n2. At least 28 days of life\n3. Diet consisting of donor human milk with\u002Fwithout mother's own milk\n\nExclusion Criteria:\n\n1. Birth weight below the 5th percentile\n2. History of necrotizing enterocolitis, spontaneous intestinal perforation, or other gastrointestinal disorder\n3. Congenital anomalies\n4. Care team discretion","28 Days",{"count":107,"type":21},20,[24],"Preterm and very low birth weight (VLBW, \\\u003C 1,500g) infants who receive donor human milk (DHM) often experience slow postnatal growth and no clinical data is available to guide the duration of DHM for preterm infants. The investigators hypothesize that transitioning from DHM to preterm infant formula after the first month of life is both safe and conveys improved weight and length gains and fat free mass accumulation.",[111,112],"Preterm Birth","Nutrition, Healthy",[114,115],"newborn","human milk","2025-08-19",{"date":118,"type":33},"2025-08-24",{"date":120,"type":33},"2025-05-01",{"date":122,"type":21},"2027-06-30",{"name":39,"class":40},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100600336","afterschool-rx-20-prescriptions-to-afterschool-care-for-pediatric-cardiovascular-risk-reduction-100600336","NCT07096167","Afterschool Rx 2.0: Prescriptions to Afterschool Care for Pediatric Cardiovascular Risk Reduction","Advancing Pediatric Cardiovascular Health Through Afterschool Care: A Preliminary Randomized Controlled Trial","ARx","Inclusion Criteria:\n\n* A child must be entering 1st-4th grade when recruited (i.e., 5-11 years old)\n* A child must have one or more cardiovascular risk factors as identified by a clinical care provider (i.e., obesity, hypertension, hyperglycemia, hyperlipidemia)\n* Attend an elementary school patterned with a participating afterschool program\n* Belong to a family at or below 250% of the federal poverty level\n* The participating parent\u002Fguardian must have a phone that accepts text messages\n\nExclusion Criteria:\n\n* If the child does not meet the inclusion criteria for attending the participating afterschool programs (e.g., children that require specially trained staff to safely provide care),\n* If the child is pregnant\n* If it is unsafe for the child to participate in any of the study measures as determined by their clinical care provider (i.e., can not safely complete a 6-min walk test or finger stick)","5 Years","11 Years",{"count":135,"type":21},48,[24],"The goal of this clinical trial is to learn if \"prescribing\" afterschool care to children at risk for poor heart health later in life increases their physical activity and improves their heart health. 'Prescriptions' will be provided by pediatricians at participating Federally Qualified Health Centers and vouchers to existing afterschool programs (e.g., YMCA, Boys and Girls Clubs) will be provided by the research study. The main questions this study aims to answer are:\n\nCan afterschool care providers and health care providers easily offer and keep using the voucher program?\n\nWill families use the voucher? Do they go to afterschool care regularly, and do the families who use them represent a wide range or backgrounds?\n\nDoes going to afterschool care help children be more physical activity?\n\nDoes going to afterschool care improve heart health?\n\nResearchers will compare two randomly assigned time periods; one semester when families get the voucher and one semester where they do not. They will look at whether use of the afterschool care voucher leads to more physical activity and improved heart health.",[139],"Cardiovascular Risk Factor",[141,142,143,144,145],"cardiovascular","out-of-school time","afterschool care","pediatric","physical activity","NOT_YET_RECRUITING","2025-07-30",{"date":149,"type":33},"2025-08-03",{"date":151,"type":21},"2025-08",{"date":153,"type":21},"2028-05",{"name":39,"class":40},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":165,"phases":4,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":182,"leadSponsor":184,"locationsCount":41},"100585870","a-study-comparing-short-course-antifungal-therapy-scat-7-day-vs-standard-14-day-antifungal-therapy-for-uncomplicated-candidemia-100585870","NCT06907992","A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia","Short-Course Antifungal Therapy vs Standard of Care (14 Day Therapy) for Uncomplicated Candidemia (SCAT)","SCAT","Inclusion Criteria:\n\n1. Patients ≥ 18 years of age\n2. Uncomplicated candidemia (positive blood culture only). No evidence of invasive candidiasis at day 1 or until day 7.\n3. Received \\\u003C 5 days of prior antifungal therapy\n4. Informed Consent for randomization\n5. Patients that did not consent to randomization have consented to be used as a natural history (controls) and will allow collection of available data from the medical record.\n\nExclusion Criteria:\n\n1. Inadequate source control (e.g., unable to remove endovascular devices, urinary catheters).\n2. Invasive candidiasis of any type (e.g., deep seated candidiasis from sources other than blood)\n3. Abnormal LFTs \\> 10-fold\n4. Greater than 5 days of prior antifungal therapy\n5. Endovascular devices that cannot be removed.\n6. Immunocompromised patients (AIDS\u002FHIV; solid organ transplant, bone marrow transplant patients, oncology patients receiving chemotherapy, neutropenic patients (ANC of \\\u003C 1,500 cells\u002FL\n7. Neutropenic at time of consent (what does this mean)\n8. Break-through candidemia (people with prior candidemia who relapsed) after treatment with antifungal therapy)\n9. Unable to provide informed consent from either the patient or legally authorized authority (LAR)\n10. Expected mortality within 96 hours",{"count":164,"type":21},150,"OBSERVATIONAL","The goal of this clinical trial is to assess whether a seven-day course of standard of care (echinocandin) antifungal therapy is non-inferior to a 14-day course of echinocandin antifungal therapy in patients with uncomplicated candidemia in terms of clinical, mycologic, adverse events and all cause mortality.",[168],"Candidemia",[170,171,172,173,174,175,176,177],"candidemia","uncomplicated candidemia","antifungal therapy","echinocandin","caspofungin","micafungin","rezafungin","anidulafungin","2025-04-02",{"date":180,"type":33},"2025-04-04",{"date":120,"type":21},{"date":183,"type":21},"2027-12-31",{"name":39,"class":40},{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":165,"phases":4,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":4},"100585379","sugammadex-reduces-antiemetic-effect-of-dexamethasone-100585379","NCT06901596","Sugammadex Reduces Antiemetic Effect of Dexamethasone","Inclusion Criteria:\n\n* Older than 18 years old\n* Elective surgery\n* ASA 1, 2, 3\n* At least one risk factor for PONV\n\nExclusion Criteria:\n\n* Pregnancy\n* Receiving antiemetics prior to arrival to preoperative holding area\n* Receiving opioids prior to arrival to preoperative holding area\n* Admission to ICU\n* Altered mental status\n* Rapid sequence induction\n* Nausea or vomiting before surgery",{"count":192,"type":21},100,"Sugammadex is a medication used for reversal of muscle relaxation during procedures under general anesthesia. It works by encapsulating muscle relaxant molecules with a steroid ring in its structure. On the other hand, postoporative nause and vomiting (PONV) is an adverse outcome during anesthesia. PONV can be prevented with pharmacologic agents such as ondansetron and dexamethasone. Dexamethasone is a steroidal agent that can interact with sugammadex. In theory, this interaction could lead to reduced effectiveness of sugammadex. In fact, several studies have explored this interaction. However, the effect of sugammadex on the antiemetic effect of dexamethasone has not been evaluated. This study intends to evaluate this interaction.",[195],"PONV",[197,198,195,199,200],"sugammadex","dexamethasone","perioperative","surgery","2025-03-23",{"date":203,"type":33},"2025-03-30",{"date":205,"type":21},"2025-04-01",{"date":207,"type":21},"2025-07-15",{"name":39,"class":40},{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":215,"maxAge":49,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":41},"100582050","the-impact-of-meditation-on-anxiety-and-post-operative-pain-in-pediatric-patients-undergoing-urological-surgery-100582050","NCT06858267","The Impact of Meditation on Anxiety and Post-Operative Pain in Pediatric Patients Undergoing Urological Surgery","Inclusion Criteria:\n\n* Age 6-18\n* Pediatric urology patients at Children's Healthcare of Georgia in Augusta, GA; scheduled for any urological surgery\n* Otherwise, healthy patients\n* Must record any medical history and medications\n* Must record prior attempts of meditation therapy\n* Children must provide assent\n\nExclusion Criteria:\n\n* History of any prior surgeries\n* History of anxiety or anxiety-related disorders\n* Diagnosis of developmental delay","6 Years",{"count":217,"type":21},60,[24],"1. The aim of this study is to assess anxiety in pediatric patients preoperatively, perioperatively, and postoperatively and whether meditation reduces anxiety in the days before, during, and after the surgery.\n2. The second aim of this study is to see if longitudinal meditation is associated with decreased postoperative pain by examining whether the group prescribed meditation has reduced pain medication intake, measured by the frequency of liquid analgesic medicine intake.",[221],"Pediatric Kidney Disease",[213],"2025-03-05",{"date":225,"type":33},"2025-03-07",{"date":227,"type":21},"2025-03-01",{"date":229,"type":21},"2028-12-30",{"name":39,"class":40},{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":239,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":22,"phases":242,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":252,"leadSponsor":254,"locationsCount":41},"100582341","breathe-free-a-pilot-feasibility-trial-100582341","NCT06862050","BREATHE Free: a Pilot Feasibility Trial","BREATHE Free: Character Strength and Resilience-Based Curriculum for Successful Tobacco Treatment: a Pilot Feasibility Trial","BF","Inclusion Criteria:\n\n* Daily use of one or more tobacco products\n* Valid home address in Augusta or the CSRA\n* Functioning telephone number\n* Speak, read, write in English\n\nExclusion Criteria:\n\n* Current use of tobacco cessation medications\n* Enrolled in tobacco treatment program",true,{"count":241,"type":21},90,[24],"The overall purpose of this pilot study is to assess the feasibility and acceptability of an in-person faith-based intervention to help people stop tobacco use. The study will address use of different types of tobacco products, such as smoking combustible cigarettes, cigarillos and little filtered cigars, and using\u002Fvaping electronic nicotine delivery systems (vape pens, e-cigs, and JUUL).\n\nThe intervention consists of 12 weekly meetings in which participants will go through BREATHE Free, a study guide curriculum designed to teach character strengths and promote resilience. This pilot research will provide information and practical lessons on how to improve Breathe Free implementation, increase engagement of the local people, and maximize their benefit.\n\nThe main questions it aims to answer are:\n\n* Do participants find BREATHE Free curriculum acceptable, engaging and helpful to stop tobacco use?\n* Do participants who complete BREATHE Free curriculum smoke fewer cigarettes per day?\n\nResearchers will assign participants to either BREATHE Free curriculum or usual care.\n\nParticipants will:\n\n* Be taught BREATHE Free curriculum or be given information and referral to tobacco quit line\n* BREATHE Free group will attend 12 group meetings held on the university campus\n* All participants will answer interview questions related to tobacco use, character strengths and resilience\n* Expired Carbon Monoxide (CO) will be assessed in all participants.",[245,246,247],"Smoking Cessation; Tobacco Dependence","E-Cig Use","Nicotine Dependence, Other Tobacco Product","2025-03-03",{"date":250,"type":33},"2025-03-06",{"date":227,"type":21},{"date":253,"type":21},"2026-12-25",{"name":39,"class":40},{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":262,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":4},"100580898","universal-genetic-testing-of-patients-with-hematological-malignancies-ugt-100580898","NCT06843291","UNIVERSAL GENETIC TESTING OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES (UGT)","Inclusion Criteria:\n\n\\- a. Age ≥ 18 years of age. b. A new diagnosis of HM. c. Diagnostic bone marrow to be performed at Wellstar MCG Health\u002FGeorgia Cancer Center.\n\nd. Ability and willingness to provide informed consent in English to undergo skin biopsy for fibroblast culture and NGS for comparison with the BM NGS.\n\nExclusion Criteria:\n\n* There are no exclusion criteria.",{"count":192,"type":21},[24],"We propose to perform NGS and OGM with DNA extracted from bone marrow (BM; site of cancer) and NGS on skin fibroblast DNA (proxy for germline) on all patients with hematologic malignancies (HM) who undergo a standard-of-care BM biopsy at Georgia Cancer Center\u002FWellstar MCG Health. Simultaneous 4 mm punch skin biopsy for fibroblast culture will be obtained at the planned puncture site of the BM biopsy. The bone marrow biopsy and aspirate are already part of the patient's scheduled medical evaluation and the punch biopsy of the skin is the only additional procedure involved in the study.",[265],"Hematologic Disease",[267,268],"Genetic testing","hematological malignancies","2025-02-20",{"date":271,"type":33},"2025-02-24",{"date":273,"type":21},"2025-02",{"date":275,"type":21},"2029-02",{"name":39,"class":40},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":239,"sex":16,"minAge":49,"maxAge":17,"enrollmentInfo":285,"targetDuration":4,"studyType":22,"phases":287,"briefSummary":288,"conditions":289,"keywords":291,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":41},"100512755","lifestyle-intervention-for-healthy-change-100512755","NCT05956574","Lifestyle Intervention for Healthy Change","Healthy Living: Incorporating Lifestyle Interventions to Encourage a Reduction in Body Weight.","LIVE WELL","Inclusion Criteria:\n\n* Age 18-40 years\n* BMI \\> 25 kg\u002Fm2\n* No cardiopulmonary disease\n* stable on medications for 3 months\n* weight stable (+\u002F-5 pounds) for the past 3 months\n* Not pregnant or trying to get pregnant\n* Owns a smartphone\n* Able to walk unassisted\n* Not on supplemental oxygen\n\nExclusion Criteria:\n\n* Under the age of 18 years\n* 40 years and older\n* Unable to participate in an exercise program\n* Currently pregnant",{"count":286,"type":21},125,[24],"The purpose of this study is to determine the effectiveness of a physician led, multi-disciplinary approach to treating obesity that incorporates nutrition (mainly, using genetics to identify appropriate food intake), exercise, and motivational counseling. The investigators plan to recruit overweight\u002Fobese (BMI\\>25) males and females to participate. Participants will be randomized to receive a personalized diet plan, or a standard care diet plan; both groups will participate in the exercise intervention. For a 6-month duration, both groups will be asked to improve their diet according to their dietary plan and participate in moderate-to-vigorous physical activity (gradual increase up to 300 min\u002Fweek). The investigators intend to evaluate standard outcomes of weight loss, and assess for any predictors of positive outcomes. Following the six-month intervention, participants will complete a 3-month no contact phase. This no contact phase will provide insight into the effects of the study on weight loss maintenance. Our team also plans to address acceptability by providing evaluations to study participants and conducting interviews with a small subset of participants to improve the intervention for the future.",[290],"Overweight and Obesity",[145,292],"dietary intervention","2025-02-17",{"date":295,"type":33},"2025-02-19",{"date":297,"type":21},"2025-04",{"date":299,"type":21},"2027-05",{"name":39,"class":40},{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":239,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":41},"100446780","health-benefits-of-whole-body-vibration-100446780","NCT05097885","Health Benefits of Whole-body Vibration","Pilot Investigation on the Health Benefits of Sub Acute (12 Week) Whole-body Vibration Training","VIBE-Rx","Inclusion Criteria:\n\n* Men and women (\\> 18 yrs old)\n* All races\n\nExclusion Criteria:\n\n* \\\u003C18 years old\n* Clinical diagnosis of hepatic, cardiovascular, or renal disease\n* Diabetic complications (i.e. macrovascular, microvascular, or autonomic)\n* Pregnancy\n* Direct vasoactive medications (i.e. nitrates)",{"count":310,"type":21},40,[24],"The overall goals of this pilot investigation are to determine 1) the feasibility of conducting home based WBV studies, and 2) to determine if sub-acute home based WBV can improve a) exercise capacity, b) conduit- and micro- vascular function, and c) skeletal muscle function.",[314],"Whole-body Vibration","2025-01-27",{"date":317,"type":33},"2025-01-28",{"date":319,"type":33},"2022-02-28",{"date":321,"type":21},"2028-01-01",{"name":39,"class":40},{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":239,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":41},"100396983","early-phase-1-type-1-diabetes-endothelin-and-skeletal-muscle-mitochondrial-dysfunction-the-role-of-sirtuin-1-100396983","NCT04449198","Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1","T-St1M","Inclusion Criteria:\n\n* Men and premenopausal women\n* All races\n* Clinical diagnosis of insulin-dependent type 1 diabetes (patients only)\n\nExclusion Criteria:\n\n* Clinical diagnosis of hepatic, cardiovascular, or renal disease\n* Uncontrolled diabetes (HbA1C \\>12%)\n* Diabetic complications (i.e. neuropathy)\n* Uncontrolled hypertension (\\>140\u002F90 mm Hg on therapy)\n* Pregnancy\n* Use of vasoactive medications",{"count":331,"type":21},24,[53],"The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.",[335],"Type 1 Diabetes",[337,338,339,340],"diabetes","heart disease","muscle function","blood vessels",{"date":317,"type":33},{"date":343,"type":33},"2020-10-14",{"date":345,"type":21},"2027-07-01",{"name":39,"class":40},{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":357,"briefSummary":359,"conditions":360,"keywords":362,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":41},"100561303","phase-3-olanzapine-25-vs-5-mg-in-quadruplet-nauseavomiting-prophylaxis-before-high-dose-melphalan-100561303","NCT06588413","Olanzapine 2.5 vs 5 mg in Quadruplet Nausea\u002FVomiting Prophylaxis Before High-Dose Melphalan","Randomized, Double-Blind Study of FOND (Fosaprepitant, ONdansetron, Dexamethasone) Plus Either Olanzapine 2.5 mg Versus 5 mg for the Prevention of Chemotherapy Induced Nausea and Vomiting in Patients Receiving High-dose Melphalan Conditioning: The FONDO-LOW Study","FONDO-LOW","Inclusion Criteria:\n\n* Receipt of high-dose melphalan 140-200 mg\u002Fm2\n* Autologous stem cell transplantation recipient\n\nExclusion Criteria:\n\n* Allergy to olanzapine\n* Documented nausea or vomiting within 24 hours prior to enrollment\n* Treatment with other antipsychotic agents such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone within 30 days prior to enrollment or planned during protocol therapy\n* Chronic alcoholism\n* Pregnant\n* Decline or unable to provide informed consent",{"count":356,"type":21},172,[358],"PHASE3","Patients who receive a chemotherapy called melphalan are at high risk of having nausea and vomiting. A medication called olanzapine has been shown to decrease nausea and vomiting after chemotherapy. A previous research study found the 10 mg dose of olanzapine (combined with 3 standard medications used routinely to prevent nausea\u002Fvomiting) to be effective for patients who received melphalan chemotherapy, but several other studies have shown many patients have a side effect of sleepiness (e.g., sedation) with that dose of the medication. Our study will compare two lower doses of olanzapine (5 mg and 2.5 mg) in combination with the 3 standard medications used to prevent nausea\u002Fvomiting in the patients who receive melphalan chemotherapy to determine which dose is effective in preventing nausea and vomiting with the lowest amount of sleepiness side effect.",[56,361],"Autologous Stem Cell Transplantation",[363,364,365,366,367],"CINV","Nausea","Olanzapine","Melphalan","autologous transplant","2024-11-20",{"date":370,"type":33},"2024-11-22",{"date":372,"type":33},"2024-09-17",{"date":374,"type":21},"2027-10",{"name":39,"class":40},{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":239,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":22,"phases":384,"briefSummary":385,"conditions":386,"keywords":388,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":41},"100551770","virtual-reality-during-exercise-testing-100551770","NCT06464406","Virtual Reality During Exercise Testing","Effects of Virtual Reality on Cardiorespiratory Fitness Test Results","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n* Answering \"YES\" to one or more items on the Physical Activity Readiness Questionnaire (PAR-Q).\n* Women who are pregnant at the time of participation according to a pregnancy test.",{"count":331,"type":21},[24],"The goal of this clinical trial is to explore the effects of virtual reality use on maximal aerobic exercise test performance (aerobic capacity) in healthy adults. The main questions it aims to answer are:\n\n* Does using a virtual reality program during a maximal aerobic exercise test lead to differences in VO2peak (maximal aerobic capacity)? and,\n* Does using a virtual reality program during a maximal aerobic exercise test lead to differences in work rate at the ventilatory threshold?\n\nParticipants will complete a maximal aerobic exercise test two times (separated by 1 week of recovery) under the following conditions:\n\n* normal testing conditions in a lab\n* while viewing a virtual reality video\n\nResearchers will compare the test results of both conditions to see if the use of a virtual reality program alters VO2peak or the ventilatory threshold.",[387],"Virtual Reality",[389,390,391,392],"virtual reality","cardiorespiratory fitness","anaerobic threshold","bicycle ergometer test","2024-06-19",{"date":395,"type":33},"2024-06-21",{"date":397,"type":33},"2024-06-07",{"date":399,"type":21},"2024-10-07",{"name":39,"class":40},{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":22,"phases":411,"briefSummary":412,"conditions":413,"keywords":417,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":41},"100498541","home-biofeedback-therapy-for-dyssynergic-defecation-fecal-incontinence-and-urinary-incontinence-100498541","NCT05771597","Home Biofeedback Therapy for Dyssynergic Defecation, Fecal Incontinence and Urinary Incontinence","Home Biofeedback Therapy for Dyssynergic Defecation, Fecal Incontinence and Urinary Incontinence: Randomized Study","Bioanatoner","Inclusion Criteria:\n\n* Inclusion Criteria for patients with constipation and dyssynergic defecation\n\n  1. Minimum age of 18 years\n  2. Meet Rome IV criteria for functional constipation (≥ 2 of following 6 symptoms) with symptom onset of 6 months on prospective stool diary\n* Straining with 25% of bowel movements (BM)\n* Lumpy or hard stools (Form 1 of 2 on the Bristol Stool Scale) with 25% of BM\n* Sensation of incomplete evacuation with 25% of BM\n* Sensation of anorectal obstruction\u002Fblockage with 25% of BM\n* Manual maneuvers to facilitate defecation with 25% of BM\n* \\\u003C 3 Spontaneous bowel movements per week 3. Patients must demonstrate dyssynergic pattern of defecation (Types I-IV), during repeated attempts to defecate, and defined as a paradoxical increase in anal sphincter pressure (anal contraction), or less than 20% relaxation of the resting anal sphincter pressure, or inadequate propulsive forces during anorectal manometry.\n\n  * Dyssynergic pattern of defecation on anorectal manometry plus one or more of the following criteria:\n  * Inability to expel an artificial stool (50 mL water-filled balloon) within 1 minute.\n  * Prolonged colonic transit time on wireless motility capsule (\\>59 hours) or \\>5 markers retained on a colonic transit study.\n  * Inability to evacuate or ≥ 50% retention of barium during defecography.\n\nInclusion Criteria for patients with fecal incontinence\n\n1. Minimum age of 18 years\n2. Recurrent episodes of fecal incontinence for six months\n3. No colonic mucosal disease\n4. On a two-week, prospective stool diary, patient reports at least one episode of fecal incontinence per week\n\nInclusion Criteria for patients with urinary incontinence\n\n1. Minimum age of 18 years\n2. Recurrent episodes of urinary incontinence for three months\n3. Stress, urge or mixed urinary incontinence, with at least 2 episodes of urinary incontinence on a 14-day urinary incontinence diary\n\nExclusion Criteria:\n\n* Exclusion criteria for patients with constipation and dyssynergic defecation\n\n  1. Evidence of structural or metabolic disease that could cause constipation, as assessed by colonoscopy or barium enema and routine hematological, biochemical, and thyroid function tests\n  2. Use of opioids within the previous 2 weeks\n  3. Severe cardiac or renal disease\n  4. Neurological diseases such as multiple sclerosis or stroke\n  5. Rectal prolapse or active anal fissures\n  6. Alternating pattern of constipation and diarrhea\n  7. Pregnant women or nursing mothers\n* Exclusion criteria for patients with fecal incontinence Severe diarrhea with Bristol Stool consistency ≥ Type 6 2. On opioids (except on stable doses \\> 3months) 3. Active depression 4. Comorbid illnesses, severe cardiac disease, chronic renal failure or severe Chronic Obstructive Pulmonary Disease (COPD) 5. Ulcerative and Crohn's colitis 6. Rectal prolapse or active anal fissure 7. Pregnant women or nursing mothers\n* Exclusion criteria for patients with urinary incontinence\n\n  1. Continuous urine leakage\n  2. Active depression\n  3. Comorbid illnesses, severe cardiac disease, chronic renal failure or severe COPD\n  4. Rectal prolapse or active anal fissure\n  5. Pregnant women or nursing mothers",{"count":410,"type":21},72,[24],"Biofeedback therapy is an effective treatment for the management of patients with dyssynergic defecation and constipation, urinary incontinence (UI), and fecal incontinence (FI). It is labor-intensive, costly, requires multiple office or hospital visits, is not easily available to the vast majority of patients in the community, and is not covered by many insurance companies.\n\nThe purpose of this study is to\n\n1. Evaluate home biofeedback therapy for patients with either constipation and dyssynergic defecation or urinary leakage or stool leakage by assessing the efficacy and safety of a wireless anorectal biofeedback device, and a cellphone app-based and voice guided home biofeedback training system\n2. To compare the efficacy and safety of home biofeedback therapy system with the standard of care, office biofeedback therapy\n3. To assess the cost-effectiveness of home biofeedback therapy.",[414,415,416],"Fecal Incontinence","Dyssynergic Defecation","Urinary Incontinence",[418,419,420,421,422],"home biofeedback therapy","office biofeedback therapy","fecal incontinence","dyssynergic defecation","urinary incontinence","2023-03-14",{"date":425,"type":33},"2023-03-16",{"date":427,"type":21},"2023-03-27",{"date":429,"type":21},"2026-12-31",{"name":39,"class":40},{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":16,"minAge":439,"maxAge":49,"enrollmentInfo":4,"targetDuration":4,"studyType":440,"phases":4,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":444,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":41},"100239650","epidiolex-and-drug-resistant-epilepsy-in-children-100239650","NCT02397863","Epidiolex and Drug Resistant Epilepsy in Children","An Open Label, Multi-Center Study to Investigate the Safety of Cannabinoid (GWP42003-P) in Children With Medication Resistant Epilepsy","CBD","Inclusion Criteria:\n\n* Patient should have history of trying at least four antiepileptic drugs (AEDs), including one trial of a combination of two concomitant drugs, without successful seizure control. Vagal nerve stimulation, RNS deep brain stimulation, or the ketogenic diet can be considered equivalent to a drug trial.\n* Patient must be taking two or more AEDs at a dose which has been stable for at least four weeks.\n* A State of Georgia resident.\n\nExclusion Criteria:\n\n* Patient is diagnosed as having Dravet Syndrome or Lennox-Gastaut Syndrome and eligible for a GW Pharmaceutical-Sponsored Clinical Trial.\n* Patients who have been part of a clinical trial involving another investigational product in the previous six months.","1 Year","EXPANDED_ACCESS","This open-label, multi-center study is open to patients 1 to 18 years of age at time of enrollment with medication resistant epilepsy.",[443],"Epilepsy","AVAILABLE","2015-04-23",{"date":447,"type":21},"2015-04-24",{"date":449,"type":4},"2014-12",{"date":451,"type":21},"2020-01",{"name":39,"class":40},""]